Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOVON 173 AML: ivosidenib + azacitidine with or without venetoclax in newly diagnosed IDH1-mutated AML or MDS/AML
2024-512753-24-00Phase 3Authorised
- Sponsor
- HOVON
- Start
- Aug 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) comparing Ivosidenib + azacitidine + venetoclax with Ivosidenib + azacitidine + placebo (2 arms). Primary endpoint: Event-free survival. Planned start Aug 2025; status: authorised.
02
Drugs
ivosidenibazacitidinevenetoclax
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2024-512753-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512753-24-00.